Eli Lilly, Novo Nordisk soar with demand for weight loss drugs
Lilly has more than doubled in a year, while Denmark’s Novo Nordisk is up by two-thirds.
Investing. Plain and simple.
Lilly has more than doubled in a year, while Denmark’s Novo Nordisk is up by two-thirds.
Elil Lilly and Novo Nordisk have head start on market projected to hit $100B in US by 2030.
Shipping costs and chip shortages have eased as demand for elective surgeries has recovered
Celebrity endorsements helping build market potential, analysts say
Slowing growth in core businesses, plus recalls and bribery allegation have worried investors
Considered dull during the tech boom, these mature, global businesses are back in favour.
Two types of Real Estate Investment Trust outperformed during the pandemic.
View post to subscribe to site newsletter.
UK-based firm has lost more than half of its value since its October IPO which raised money for US expansion.
Much delayed and needed elective surgeries are getting back on track as the latest wave of COVID-19 infections eases.
It should be another good year, but share prices may have limited upside.
You must be logged in to post a comment.